Načítá se...

The clinical utility of aflibercept for diabetic macular edema

The treatment of center-involving diabetic macular edema (DME) has improved because of the proven efficacy of drugs that inhibit the effects of vascular endothelial growth factor (VEGF). The newest anti-VEGF drug, aflibercept, has recently been approved by the United States Food and Drug Administrat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Metab Syndr Obes
Hlavní autor: Stewart, Michael W
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2015
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4583120/
https://ncbi.nlm.nih.gov/pubmed/26425104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S72792
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!